UNSPSC 51192200: Combination diuretics

This classification denotes combination drugs and preparations that promote excretion of urine by influencing human kidney function, commonly known as DIURETICS. The major diuretic types include osmotic (diuretics that increase urine volume by increasing osmotically-active urine solute); potassium sparing (diuretics that limit potassium secretion in urine); sodium chloride symporter inhibitors; and sodium potassium chloride symporter inhibitors.

Diuretics, that is, operate by stimulating he nervous system, by alleviating kidney congestion, by increasing blood pressure, or by increasing or improving liquid transport. Typical combination diuretic constituents are hydrochlorothiazide, potassium chloride, spironolactone, and triamterene.

UNSPSC 51192200 Combination diuretics, a Class code, shows minimal recent state and local procurement activity directly aligned with the code's pharmaceutical scope. The single recent opportunity clearly related to the code's nominal function is the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP issued January 20, 2026, seeking generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities, including Oregon, with proposals due March 26, 2026. The second recent opportunity posted under this code — the City of Meriden's July 8, 2026 solicitation for sodium bisulfite chemical supply for water treatment — is unrelated to the code's pharmaceutical scope and appears to be a tagging mismatch. The code's actual procurement activity centers on multi-source pharmaceutical contracts managed through cooperative purchasing vehicles, where state health and human services agencies source generic drugs and OTC products through authorized pharmaceutical wholesalers for use across state and local facilities.

The MMCAP opportunity represents the issuing-body model most relevant to this code: cooperative purchasing alliances administered by state departments of administration or procurement offices, serving multiple participating jurisdictions. The geographic spread of recent activity is limited; only Minnesota (as the MMCAP lead state) and Oregon (as a participating member) surface in the current opportunities. Vendors pursuing MMCAP contracts must be manufacturers certified under current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health 110 and 112, and Morris & Dickson), and comply with NDC and SKU submission requirements. MMCAP evaluates proposals on price competitiveness (75 percent), fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Contract terms run two years for new vendors with optional extensions, or align with incumbent expiration dates through June 30, 2028. General activity under the code is light relative to broader pharmaceutical procurement, suggesting either limited statewide use of diuretics through cooperative vehicles or fragmentation across individual agency contracts not yet reflected in posted opportunities.